Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

Karolinska Institutet professor earns 2011 ECNP Neuropsychopharmacology Award

This year's ECNP Neuropsychopharmacology Award in Basic Science Research has been conferred upon Bertil Fredholm at the 24th Congress of the European College of Neuropsychopharmacology (ECNP) on 3-7 September 2011 in Paris, France.

16 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

Severe combined immunodeficiency treated successfully with gene therapy

Gene therapy can offer a cure for a rare condition that causes children’s immune systems to fail. In this rare condition, known as Severe Combined Immunodeficiency (SCID), inherited genetic mutations mean that babies are unable to fight off infection, severely limiting their chances of surviving more than a few years. Severe combined immunodeficiency (SCID) is a rare genetic disorder estimated to affect between 1 in 200,000 and 1 in 1,000,000 live births

26 Aug 2011

AstraZeneca announces availability of BRILINTA tablets in the U.S. pharmacies

AstraZeneca today announced that BRILINTA tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.

23 Aug 2011

No effective treatment yet for acute lung injury

Patients can essentially drown in their own fluids when trauma and infection prompt blood vessels to leak, flooding millions of air sacs in their lungs.

22 Aug 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

New finding about cell metabolism may have implications for neurodegenerative disorders

Cells are the building blocks of the human body. They are a focus of scientific study, because when things go wrong at the cellular and molecular level the consequences for human health are often significant.

8 Aug 2011

ArQule second quarter net loss increases to $10,804,000

ArQule, Inc. today announced its financial results for the second quarter of 2011.

4 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

Glucose meters with functional DNA can detect a broad range of targets in a solution

Glucose meters aren't just for diabetics anymore. Thanks to University of Illinois chemists, they can be used as simple, portable, inexpensive meters for a number of target molecules in blood, serum, water or food.

25 Jul 2011

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

Stored red blood cells lose ability to release key anti-adhesive molecule

Donated red blood cells lose a key feature that diminishes their lifesaving power the longer they have been stored, according to researchers at Duke University Medical Center.

16 Jul 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

Ketogenic diet reduces seizures in mice through adenosine A1 receptors

Some individuals with epilepsy fail to respond to treatment with conventional drugs but benefit from consuming a ketogenic diet - a high-fat, low-carbohydrate diet similar to the more commonly known Atkins diet.

24 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.

17 Jun 2011

Scientists discover new elements of blood clot-formation process

Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.

14 Jun 2011